Entity: Department of Health and Human Services (DHHS)
Body: Pharmacy and Therapeutics Committee
| Notice Title: | State Medicaid Pharmacy & Therapeutics Committee Meeting |
| Notice Tags: | Medicaid, Pharmacies |
| Meeting Location: | 288 North 1460 West Cannon Health Building, Room 114 Salt Lake City 84116 |
| Event Date & Time: |
March 15, 2012 March 15, 2012 07:00 AM - March 15, 2012 08:30 AM |
| Description/Agenda: | UTAH DEPARTMENT OF HEALTH
STATE MEDICAID PHARMACY AND THERAPEUTICS COMMITTEE
Thursday, March 15, 2012
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 114
AGENDA
Please note that persons who wish to address the P&T Committee may contact Lisa V. Hunt (lvhunt@utah.gov) at least 7 calendar days prior to the meeting. Comments from visitors, while welcome, may be limited due to time constraints
1. Welcome and Introductions..................................................Chair, Ellie Brownstein, M.D.
a. Review and Approval of Minutes
2. Update on PDL Administration…………...............................................Lisa V. Hunt, R.Ph
a. Housekeeping.
3. DUR Board Update...........................................................................Robyn Seely, PharmD.
4. H2 Antagonists
Included agents: Cimetidine, Famotidine, Nizatidine, Ranitidine
Documents: UU class review, UU list of available agents and dosage forms
a. Over view of Clinical Outcomes…………….…………Melissa Archer, PharmD
b. Other States Report…………………………………………. Lisa V. Hunt, R.Ph.
c. Public Comment
d. Board Discussion/Questions
e. Board Action
5. Next Meeting Information………………………………………… Lisa V. Hunt, R.Ph.
6. Meeting Adjourned………………………………….........Chair, Ellie Brownstein, M.D.
Public comment that responds to the materials presented by the College of Pharmacy @University of Utah is most helpful. The foundation documents used for most reviews are prepared by the Oregon Evidence-based Practice Center or the University of Utah College of Pharmacy and are posted in advance on the P&T Committee website.
Manufacturers are requested to submit any additional materials they would like reviewed as part of the process to:
Dr. Gary Oderda
College of Pharmacy
30 South 2000 East
SLC, UT 84112-5820
All materials must be clearly labeled that they are submitted for consideration as part of the state of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible) after the Oregon monograph was prepared, unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search.
Utah Medicaid P&T Schedule 2012
March 2012
H2 Antagonists
Included agents: Cimetidine, Famotidine, Nizatidine, Ranitidine
Documents: UU class review, UU list of available agents and dosage forms
April 2012
Open Meetings Act Training
Prenatal Vitamin Agents
Included agents: A-Free Prenatal [otc]; CitraNatal Harmony; CitraNatal 90 DHA; CitraNatal Assure; CitraNatal B-Calm; CitraNatal DHA; CitraNatal Rx; Concept DHA; Concept OB; Duet; Duet Balanced DHA; Femecal OB; Folcaps Care One; Foltabs Prenatal; Foltabs Prenatal Plus DHA; Gesticare; Gesticare DHA; KPN Prenatal [otc]; Mini-Prenatal [otc]; Multi-Nate 30; NataFort [otc]; Néevo; Néevo DHA; One A Day Women’s Prenatal [otc]; OptiNate; Paire OB Plus DHA; PreCare; PreferaOB; PreferaOB + DHA; PreferaOB One; Prenatabs FA; Prenatal One Daily [otc]; Prenatal Rx 1; Prenatal With Beta Carotene [otc]; Prenate DHA; Prenate Elite; Prenate Essential; PreNexa Premier; PrimaCare One; Select-OB; Stuart Prenatal [otc]; Tandem DHA; Tandem OB; TriCare Prenatal; TriCare Prenatal DHA One; Vinacal; Vinate Care; Vitafol-OB [otc]; Vitafol-OB+DHA [otc]; Vitafol-PN; VitaPhil + DHA
Documents: UU class review, UU list of available agents and dosage forms
May 2012
Antineoplastic Enzyme Inhibitors
Included agents: Crizotinib, Dasatinib, Erlotinib, Gefitinib, Imatinib, Lapatinib, Nilotinib, Pazopanib, Ruxolitinib, Sorafenib, Sunitinib, Vandetanib
Documents: UU class review, UU list of available agents and dosage forms
June 2012
Antimetabolite Agents (Antifolate agents, Purine analogs, Pyrimidine analogs)
Included agents: Capecitabine, Cladribine, Clofarabine, Cytarabine, Floxuridine, Fludarabine, Fluorouracil, Gemcitabine, Mercaptopurine, Methotrexate, Pemetrexed, Pentostatin, Pralatrexate, Thioguanine
Documents: UU class review, UU list of available agents and dosage forms
July 2012
Topical Steroids
Included agents: Alclometasone, Amcinonide, Betamethasone, Clobetasol, Clocortolone, Desonide, Desoximetasone, Diflorasone, Fluocinolone, Fluocinonide, Flurandrenolide, Fluticasone, Halcinonide, Halobetasol, Hydrocortisone, Mometasone, Prednicarbate, Triamcinolone
Documents: UU class review, UU list of available agents and dosage forms
August 2012
Cold and Cough Agents
Documents: UU class review, UU list of available agents and dosage forms
|
| Notice of Special Accommodations: | NOTICE OF SPECIAL ACCOMMODATION DURING PUBLIC MEETINGS In compliance with the Americans with Disabilities Act, individuals needing special accommodations (including auxiliary communicative aids and services) during this meeting should notify Lisa Hunt at 801-538-6317. |
| Notice of Electronic or telephone participation: | NOTICE OF POSSIBLE ELECTRONIC OR TELEPHONIC PARTICIPATION One or more members of the Pharmacy & Therapeutics Committee may participate electronically or telephonically pursuant to UCA 52-4-7.8 |
| Other information: | |
| Contact Information: |
Ngan Huynh 801-538-6155 nganhuynh@utah.gov |
| Posted on: | March 01, 2012 09:05 AM |
| Last edited on: | March 01, 2012 09:07 AM |